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Reducing the extent of secondary degeneration following spinal cord injury (SCI) is
necessary to preserve function, but treatment options have thus far been limited. A
combination of the ion channel inhibitors Lomerizine (Lom), YM872 and oxATP, to inhibit
voltage-gated Ca2+ channels, Ca2+ permeable AMPA receptors, and purinergic P2X7
receptors respectively, effectively limits secondary consequences of injury in in vitro and
in vivo models of CNS injury. Here, we investigated the efficacy of these inhibitors in
a clinically relevant model of SCI. Fischer (F344) rats were subjected to a moderate
(150 kD) contusive SCI at thoracic level T10 and assessed at 2 weeks or 10 weeks
post-injury. Lom was delivered orally twice daily and YM872 and oxATP were delivered
via osmotic mini-pump implanted at the time of SCI until 2 weeks following injury.
Open field locomotion analysis revealed that treatment with the three inhibitors in
combination improved the rate of functional recovery of the hind limb (compared to
controls) as early as 1-day post-injury, with beneficial effects persisting to 14 days
post-injury, while all three inhibitors were present. At 2 weeks following combinatorial
treatment, the functional improvement was associated with significantly decreased
cyst size, increased immunoreactivity of β-III tubulin+ve axons, myelin basic protein,
and reduced lipid peroxidation by-products, and increased CC1+ve oligodendrocytes
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AnkG, ankyrin-G; BBB, Basso, Beattie,
and Bresnahan; Ca, calcium; CNS, central nervous system; GAP43, growth-associated protein 43; GFAP, glial fibrillary
acidic protein; GluR, glutamate receptor; HNE, 4-hydroxynonenal; K, potassium; MBP, myelin basic protein; Na,
sodium; NG2, neural/glial antigen-2; OPC, oligodendrocyte progenitor cell; oxATP, oxidized adenosine triphosphate;
P2X, adenosine triphosphate-gated-cation channel family; PDGFα, platelet-derived growth factor subunit alpha; SCI,
spinal cord injury; SMI-32, anti-neurofilament H non-phosphorylated; VGCC, voltage-gated calcium channel; YM872,
[2,3-dioxo-7-(1H-imidazol-1-yl)6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl] acetic acid monohydrate.
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and NG2+ve/PDGFα+ve oligodendrocyte progenitor cell densities, compared to vehicle-
treated SCI animals. The combination of Lom, oxATP, and YM872 shows preclinical
promise for control of secondary degeneration following SCI, and further investigation of
long-term sustained treatment is warranted.
Keywords: spinal cord injury, secondary degeneration, ion channel inhibitors, glia, calcium (Ca2+), oxidative stress
INTRODUCTION
Spinal cord injury (SCI) is a seriously debilitating event that can
quickly lead to paralysis or even death, with a large physical,
emotional, and socioeconomic burden (Ditunno and Formal,
1994). In the United States alone, it is estimated that the annual
incidence of SCI injury is 17,000 each year, with approximately
282,000 persons currently living with a SCI (White and Black,
2016). Following SCI, there is an injury severity dependent
disruption of axonal pathways (Fehlings and Tator, 1995)
impairing motor, sensory and autonomic function at and below
the site of injury. Although a significant understanding of the
etiology and pathophysiology of SCI has been attained, an
effective therapeutic treatment strategy for SCI remains elusive.
When the central nervous system (CNS) is contused, or
damaged by a penetrative or compressive force, a plethora
of molecular and cellular cascades described as secondary
degeneration, exacerbate neurological damage, and functional
impairment. The acute phase of secondary degeneration in the
CNS can occur minutes to weeks following injury, with the
chronic phase appearing from within months to a year (Dihné
et al., 2001; Nashmi and Fehlings, 2001; Chen et al., 2003;
Fitzgerald et al., 2010; Payne et al., 2012; Petersen et al., 2012).
It is understood that the biochemical events associated with
secondary degeneration include, but are not limited to glutamate
excitotoxicity (Szydlowska and Tymianski, 2010; Tsutsui and
Stys, 2013) disruptions of ionic balance of K+, Na+, and Ca2+
(Choi, 1987; Stys, 2004) free radical formations and lipid
peroxidation (Kontos and Wei, 1986; Liu et al., 2004; Vaishnav
et al., 2010) with apoptosis of various cell types (Beattie et al.,
2000). Specifically, following SCI, damaged neurons release high
concentrations of the neurotransmitter glutamate (Park et al.,
2004) resulting in Ca2+ dysregulation, compromising cellular
machinery (Herrero-Mendez et al., 2009), and increasing cell
death (Duchen, 2012) along the apoptotic-necrotic continuum
(Cheung et al., 1998).
Ca2+ entry into neurons and glia in the CNS is mediated
by several channels, including voltage-gated Ca2+ channels
(VGCCs; Sattler et al., 1996; Agrawal et al., 2000) ionotropic
P2X7 receptors (Hollmann et al., 1991; North, 2002; Matute et al.,
2007) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors lacking the GluR2 subunit (Hollmann
et al., 1991). Excessive Ca2+ influx or Ca2+ -mediated
intracellular Ca2+ release following an injury can activate several
Ca2+-dependent processes leading to the overproduction of
mitochondrial free radicals, and oxidative damage such as lipid
peroxidation (Camello-Almaraz et al., 2006; O’Hare Doig et al.,
2014). Lipid peroxidation occurs when reactive oxygen species
react with polyunsaturated fatty acids, to form lipid radicals
such as 2-propenal (acrolein) and 4-hydroxynonenal (HNE;
Hamann and Shi, 2009; Vaishnav et al., 2010) consequently
disturbing cellular machineries (Refsgaard et al., 2000). Free
radical production and lipid peroxidation following SCI plays an
important role in secondary injury (Hall and Braughler, 1982;
Barut et al., 1993; Springer et al., 1997; Lewén et al., 2000;
Kamencic et al., 2001; Christie et al., 2008).
Neuropathological changes in myelin architecture contribute
to deficits in locomotor function following SCI (Guest et al.,
2005) Changes seen in myelin structure may reflect disruption
in the numbers of oligodendroglia along the differentiation
lineage, resulting in perturbed axoglial support (Nave and
Trapp, 2008). We have previously demonstrated increased
nitrosative and oxidative damage in CC1+ve mature myelinating
oligodendrocytes in vivo following a partial injury to the optic
nerve (O’Hare Doig et al., 2014) temporally and spatially
associated with changes in the node of Ranvier and paranode
axoglial structure (Szymanski et al., 2013). Oligodendrocytes
and their progenitors (oligodendrocyte progenitor cells; OPCs)
are reported to be particularly vulnerable to oxidative events
(Giacci et al., 2018b), initiating necrotic and apoptotic pathways
during CNS injury and neurodegenerative disorders such as
multiple sclerosis (Bunge et al., 1993; Thorburne and Juurlink,
1996; Juurlink et al., 1998; Gilgun-Sherki et al., 2004; Jana
and Pahan, 2007) associated with myelin abnormalities (Payne
et al., 2012, 2013; Szymanski et al., 2013; Giacci et al., 2018a)
demyelination (Griffiths et al., 1998; Matute et al., 2001; Antony
et al., 2004; Norenberg et al., 2004; Doan et al., 2013) and delayed
degeneration of axons (Crowe et al., 1997; Warden et al., 2001;
Irvine and Blakemore, 2008).
Given the significant effects of excessive Ca2+ influx on
cellular structure and function, there has been an increased
effort in the use of Ca2+ (or ion) channel inhibitors as a
treatment strategy for neurotrauma. Many of these agents such
as Lomerizine (Lom), 2,3-dioxo-7-(1H-imidazole-1-yl)6-nitro-
1,2,3,4-tetrahydro-1-quinoxalinyl acetic acid monohydrate
(YM872), and adenosine 5′-triphosphate periodate oxidized
sodium salt (oxATP) to inhibit VGCCs, Ca2+ permeable
AMPA receptors, and P2X7 receptors, respectively, have
been developed and tested in pre-clinical models and
clinical trials of Neurotrauma. Taken together, although
promising outcomes have been demonstrated in pre-clinical
studies of Ca2+ channel inhibitors, clinical trials utilizing
these agents alone for the treatment of neurotrauma alone
have been limited and overall disappointing (for review see
O’Hare Doig and Fitzgerald, 2015).
To facilitate functional recovery following CNS injury, and in
particular SCI, therapeutic strategies must overcome the volatile
environment, preserve neuronal and glial cell numbers, and
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limit changes in Ca2+ dynamics, oxidative stress, and myelin
abnormalities. It is increasingly recognized that combinatorial
treatment strategies are likely to be required to maximize
limitation of the multiple detrimental facets of neurotrauma
(Tuszynski, 2005; Kelso et al., 2011). Given the complexity
of the pathophysiology of CNS trauma, we have previously
assessed the efficacy of a variety of combinations of ion
channel inhibitors: Lom, YM872, and OxATP both in vitro
and in vivo. All three ion channel inhibitors in combination
were shown to reduce intracellular Ca2+ concentration, increase
cortical cell viability, and preserve astrocytes and neurons
following peroxide insult in vitro (O’Hare Doig et al., 2016).
Only application of Lom, YM872 and oxATP in combination
in vivo up to 3 months following partial injury to the
optic nerve limited chronic myelin decompaction and node
of Ranvier abnormalities, associated with preservation of
optokinetic reflex, indicating preservation of function, in this
model; individual inhibitors were less effective (Savigni et al.,
2013). Similarly, we have demonstrated the efficacy of this
ion channel inhibitor combination in acute partial CNS injury,
beneficial outcomes including reduced hyperphosphorylation of
tau, acetylated tubulin, and lipid peroxidation; increased Nogo-A
immunoreactivity, and preservation of AnkG lengths and OPC
numbers (O’Hare Doig et al., 2017). Therefore, it is clear that
a combination of ion channel inhibitors targeting different
pathways is beneficial in dampening the biochemical sequelae
and secondary cascade processes. However, the efficacy of the
treatment strategy must be assessed in more clinically relevant
models of neurotrauma such as SCI.
Therefore, this study was designed to further assess the
efficacy of the ion channel inhibitor combination of Lom, oxATP,
and YM872 on key events of secondary degeneration, during
the acute and chronic time phases following SCI. The Infinite
Horizon impactor device was utilized to provide a clinically
relevant, and reproducible moderate thoracic contusion model
of SCI in rodents (Anderson and Stokes, 1992), and to mimic the
pathophysiology of SCI seen in humans.
MATERIALS AND METHODS
Animals
Female Fischer rats (F344; 150–200 g) were bred at the Animal
Resources Centre (ARC; Murdoch, WA, Australia), housed
under a standard 12 h light/dark cycle, fed wet and dry rat
chow and water ad libitum. All procedures performed complied
with the ARRIVE guidelines and were carried out following the
‘‘Guide for the Care and Use of Laboratory Animals (National
Institutes of Health Publication No. 8023, revised 1978), and
were approved by The University of Western Australia’s Animal
Ethics Committee (AEC, approval number RA/3/100/1405).
Animals were of adult age at the time of experimental testing
(12–15 weeks old).
Treatments
Animals (N = 28) were randomly allocated into two cohorts:
Cohort 1 (2Weeks; 2W); SCI plus PBS vehicle (2W control; n = 7)
or SCI plus ion channel inhibitors (2W treated; n = 7); Cohort 2
(10 Weeks; 10W), SCI plus PBS vehicle (10W control; n = 7),
or SCI plus ion channel inhibitors (10W treated; n = 7). Treated
animals were administered all three ion channel inhibitors in
combination: Lom (LKT Labs, St. Paul, MN, USA), oxATP
(Sigma, St. Louis, MO, USA), and YM872 (LKT Labs, St. Paul,
MN, USA). The choice of treatment concentrations, length, and
timing of delivery was based on previously published studies
demonstrating efficacy using these agents individually and
demonstration of efficacy in the partial optic nerve transection
model (Fitzgerald et al., 2009a,b; Savigni et al., 2013). Therefore,
Lom and butter vehicle alone treatments began on the day of
surgery, after recovery from anesthesia and continued twice daily
for 2 or 10 weeks (cohort dependent). Lom mixed in butter
vehicle (30 mg/kg body weight; Tamaki et al., 2003) or butter
vehicle alone was administered orally to all animals using a
spatula, whilst animals were gently held. OxATP (1 mM; Matute
et al., 2007) and YM872 (240 µM; Savigni et al., 2013) were
delivered directly to the site of injury for the first 2 weeks after
injury via an osmotic mini-pump (see below).
Anesthesia and Surgery
Adult Fisher rats were anesthetized with 2.5% (v/v)
isoflourothane (BoMac Attane Isoflurane, Hillcrest, Auckland,
NZ, USA) combined with 60% nitrous oxide (v/v) and 38%
oxygen (v/v) for a quick and controlled recovery. A longitudinal
incision through the skin and spreading of the underlying
muscle tissue was performed, revealing the spinal column. Rats
were positioned on a surgical plate for spinal cord impact using
flexible armatures and Adson forceps (spinal cord stabilizing
forceps). Partial laminectomy at vertebral level T9-T11 exposed
the spinal cord underneath without disruption of the meninges.
Using an Infinite Horizon impactor device, animals received a
moderate T10 contusion (150 kDyne) injury to the dorsal surface
of the exposed spinal cord. Following contusion injury, the dura
was incised longitudinally, and a pre-filled osmotic mini-pump
(Model 2002; 0.5 µl/h; ALZET, Cupertino, CA, USA) attached
to a brain infusion kit (Kit 3; ALZET, Cupertino, CA, USA)
were attached and stabilized via subcutaneous sutures. The vinyl
catheter was guided underneath the skin, the brain infusion
cannula was placed above the dorsal aspect of the exposed spinal
cord, and the 30-gauge stainless steel tube was inserted directly
into the injury site. The cannula was sutured in place, muscles
were closed in layers and the incision closed with wound clips.
Rehydrating saline (2 ml subcutaneously) was administered in
conjunction with Buprenorphine (Temgesic; 0.01 ml/100 g body
weight, [(0.0324 mg/kg body weight), 300 U/ml; Provet, Malaga,
WA, Australia] immediately following surgery, and daily until
∼day 5 post-SCI. To prevent wound and bladder infections,
Benacillin [0.02 ml/100 g body weight (64 mg/kg body weight),
300 U/ml (150 mg/ml procaine penicillin, 150 mg/ml benzathine
penicillin, 20 mg/ml procaine hydrochloride); Troy Laboratories
Pty. Ltd., Glendenning, NSW, Australia] was administered
immediately after and at 2-, 4- and 6-days following surgery.
The ALZET brain infusion kits and pumps only remained
in situ for 2 weeks following SCI, as previous studies have
demonstrated reduced efficiency in delivery, and sometimes,
moderate compression damage caused by tubing, at later time
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points (Jones and Tuszynski, 2001; Hodgetts et al., 2013).
Therefore, pumps were surgically removed under anesthesia (as
described above) at 2 weeks after injury.
Behavioral Analyses—Open Field Recovery
(BBB)
Functional assessments of animals in all experimental groups
were performed on days 1–7, then weekly from weeks
2–10 following surgery (cohort dependent) and consisted of
open field locomotion assessment. Functional assessment was
conducted before surgical removal of osmotic mini-pumps at
the 2-week time-point for Cohort 2 animals. Handling and
habituation of animals to behavioral apparatus were performed
during the week before surgery.
The Basso, Beattie and Bresnahan (BBB) locomotor rating
scores were used to assess the range and type of forwarding
locomotion (Basso et al., 1995). Briefly, rats were recorded using
digital videography in an open field for 2–3 min (per hindlimb)
on days 1–7, and weekly from week 2–10 post-injury. Recordings
were made from a sideways angle, at close range for each
hindlimb, as well as views from behind the animals during the
test. Scoring of animals ranged from 0 to 21 based on the criteria
outline (Basso et al., 1995). At least two independent investigators
conducted the assessments, all blinded to experimental group
identity. Both scores for each hindlimb were averaged, and the
total average score was reported for each animal.
Tissue Preparation
Following final behavioral tests at 2- or 10-weeks post-
injury, animals were euthanized by lethal injection of sodium
pentobarbitone (50 mg/100 g; Provet, Malaga, WA, Australia)
and transcardially perfused with heparinized PBS, followed by
4% (w/v) paraformaldehyde (PFA; Sigma) in 0.1 M phosphate
buffer (pH 7.2). The vertebral columns were dissected from each
animal and postfixed in PFA for 24 h before cryoprotection in
15% (w/v) sucrose in phosphate-buffered saline (PBS; pH 7.2).
A 20 mm segment was cut from the spinal cord (containing
the lesion epicenter and rostral-caudal penumbra), ensuring
the injury site was at the midpoint, and embedded in 10%
(w/v) gelatine (Sigma, St. Louis, MO, USA) in PBS. Gelatine
blocks were trimmed and frozen at −20◦C, then embedded
in optimal cutting temperature (OCT) compound (ProSciTech;
Kirwan, QLD, Australia) and a cryostat (CM1900, Leica;Wetzlar,
Germany) used to cut longitudinal spinal cord sections (35 µm).
Consecutive series of sections were transferred to 24-well
plates containing PBS + 0.1% (w/v) sodium azide (Sigma,
St. Louis, MO, USA) and stored at 4◦C until processed for
immunohistochemistry (Figure 1).
Cyst Size Analysis
Quantification of cyst size and tissue sparing was performed
by analysis of toluidine blue-stained spinal cord sections. Every
seventh longitudinal section of the spinal cord was mounted
on slides and air-dried overnight. For all animals, the selected
sections were from the same relative location, confirmed by
histological analysis. Sections were submerged in 0.05% (w/v)
toluidine blue [in 0.0055% (w/v) sodium tetraborate; Sigma,
St. Louis, MO, USA] for 1 min then rinsed and dehydrated
sequentially in 70%, 90% and 100% (v/v) ethanol for 3 min each.
Slides were then submerged in xylene for 1 min, cover-slipped
using DPX slidemountingmedium (Sigma, St. Louis, MO, USA),
and then stored at room temperature before imaging. Data from
each of the stained sections were combined and analyzed to give a
total cyst area measurement, and total tissue area measurement,
for each animal. The cyst area was defined as the outline of the
cyst within the spinal cord section, and tissue area was defined
as the outline of the entire spinal cord section within each field
of view (FOV), using Fiji image analysis software (Schindelin
et al., 2012). The total area of cystic structures was expressed
as a percentage of total tissue area per FOV. Whilst there was
the possibility of cyst generation caused by catheter placement
in the spinal cord parenchyma, the track of the catheter (if any)
in spared tissue was visible in sections. As they are typically very
thin and distinctly different from the underlying cyst, they were
identified (if any) and excluded from the analysis.
Immunohistochemical Assessment
Selected sections within the lesion epicentre were washed
in PBS and immunohistochemical analyses conducted
according to established procedures (Fitzgerald et al., 2010;
Hodgetts et al., 2013) using primary antibodies recognising:
astrocytes, glial fibrillary acid protein (GFAP; 1:1,000; #ab53554,
Abcam, Cambridge, UK); neurons, β-III-tubulin (1:1,000;
MMS-435P-250, Jomar Bioscience, Scoresby, VIC, Australia);
non-phosphorylated neurofilaments of mature motor neurons
(SMI-32; 1:1,000; #NE1023, Merck Millipore, Burlington,
MA, USA); growth associated protein 43 (GAP43; 1:500;
#SAB4300525, Sigma, St. Louis, MO, USA); myelin basic protein
(MBP; 1:500; #ab40390, Abcam, Cambridge, UK); mature
oligodendrocytes (CC1; 1:500; #ab16794, Merck Millipore,
Burlington, MA, USA); oligodendrocyte progenitor cells (OPCs);
platelet-derived growth factor alpha (PDGFα; 1:500; #sc-9974,
Santa Cruz Biotechnology, Dallas, TX, USA) and neural/glial
antigen 2 (NG2; 1:500; #ab83178, Abcam, Cambridge, UK);
lipid peroxidation markers, acrolein (1:500; #ab37110, Abcam,
Cambridge, UK); 4-Hydroxynonenal (HNE; 1:500; #STA-035,
Jomar Bioscience, Scoresby, VIC, Australia), and Hoechst
nuclear stain (1:3,000; #62249, Invitrogen, Carlsbad, CA, USA).
Secondary antibodies were species-specific AlexaFluorr 488,
555, and 647 (1:400; Life Technologies, Carlsbad, CA, USA)
respective for each primary antibody.
Immunohistochemical Analysis and
Semi-quantification
Immunohistochemical labeling was visualized in a single selected
section of the spinal cord, in the immediate area surrounding
the lesion site for each animal and photographed using either an
upright Eclipse E800 microscope (Nikon Corporation, Minato,
Tokyo, Japan) or, where co-localization and cellular densities
were quantified, a Nikon Eclipse Ti inverted microscope (Nikon
Corporation, Minato, Tokyo, Japan). For all outcomes and
tissues, images were collected at set constant exposures in a
single sitting where possible, and immunointensity analyses
were conducted on six 200 µm × 200 µm regions of interest
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FIGURE 1 | Study design. Following sham or spinal cord injury (SCI) surgery, two cohorts of animals (N = 28) were treated daily with butter (orally) or lomerizine
(30 mg/kg, orally), and saline or oxATP + YM872 via osmotic mini-pump. Daily behavioral analyses were conducted for the first week following surgery, and then
weekly thereafter. Surgical removal of pumps occurred in Cohort 2 animals, only. At 2 weeks (Cohort 1; n = 14) or 10 weeks following surgery (Cohort 2; n = 14),
animals were humanely killed and tissue was harvested for analysis. ∗Total number of animals included in behavioral and histological analysis.
(ROIs; dorsorostral, centrorostral, ventrorostral, dorsocaudal,
centrocaudal and ventrocaudal) immediately adjacent to the
injury site (Figure 2) using Fiji analysis software (Schindelin
et al., 2012). Constant arbitrary threshold intensities for all
images for a marker relative to the background (black, no tissue)
were set to account for potential variation in section thickness
and antibody application, and mean intensities and areas
above-set threshold were semi-quantified. As normalization to
the background is not possible for oxidative stress data, as
oxidized proteins and DNA are diffusely distributed throughout
individual cells and or tissue, data relative to other proteins was
not normalized. Note that pilot analyses comparing outcomes
between the six ROI for analyzed tissue sections within each
experimental group did not reveal differences and so data for
the six ROI for each tissue section (i.e., animal) were averaged
and these means used for further statistical interpretation.
Only the mean intensity above threshold rather than the area
of immunointensities above the threshold is shown in the
following results unless stated within the text. Cell-type-specific
densities were quantified through a series of optical images at six
individual ROIs at 1 µm increments along the z-axis, acquired
from themiddle 9µmof each cord section. All images were taken
in areas surrounding the injury site, where no evidence of cystic
structures was present. This ensured any observable changes in
immunopositive areas and cell population densities were not
due to physical disturbances of spinal cord tissue. Secondary
antibody-only controls were processed concurrently to ensure
the selectivity of staining (data not shown).
Statistical Analyses
Mann–Whitney U test for non-parametric data was used to
analyze open field locomotion testing (BBB analysis) data,
comparing control vs. treated at each time point in separate
analyses for the animals euthanized at 2 or 10 weeks. Statistical
analyses of cyst size and semi-quantitative immunohistochemical
FIGURE 2 | Schematic diagram demonstrating regions of interest (ROIs) in a
selected section of the spinal cord for immunohistochemistry.
Immunohistochemical labeling was visualized in a selected section of the
spinal cord, in the immediate penumbra surrounding the lesion site (cyst).
Images were collected from six 200 µm × 200 µm regions of interest (black
box; dorsorostral, centrorostral, ventrorostral, dorsocaudal, centrocaudal, and
ventrocaudal) immediately adjacent to the injury site (A; not to scale). Stitched
×10 gray scale fluorescent image demonstrates cord injury site and evidence
of cystic structures (B).
assessments were conducted using a two-way ANOVA followed
by Sidak’s multiple comparisons test. All statistical analyses
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were performed using GraphPad Prism version 7.00 (GraphPad
Software). All data assumes equal variance unless otherwise
stated. All data were presented as the mean ± standard
error of the mean. Adjusted P values ≤ 0.05 were considered
statistically significant. For post hoc analyses of cyst size and
immunohistochemical assessments, comparisons were made
between 2W control vs. 2W treated, 10W control vs. 10W treated,
2W control vs. 10W control, and 2W treated vs. 10W treated. No
sample calculation was performed. The sample size was based on
previous research in our laboratory.
RESULTS
Short Term Combinatorial Ion Channel
Inhibitor Treatment Facilitated Significant
Early Hindlimb Functional Recovery That
Was Not Sustained
Following injury, animals demonstrated significant locomotor
deficits in the hind limbs. Animals demonstrating weight support
on the hindlimbs (BBB score ≥9) 24 h following SCI was
excluded from both behavioral and histological analysis. These
observations typically correlate with an unsuccessful impact of
the cord. This only occurred once in each cohort, of the vehicle-
treated groups. One animal from 2W + PBS and 10W + PBS
groups were removed from the study analysis. Two cohorts of
rats were scored daily for 7 days, and then once weekly thereafter
on their ability to generate spontaneous, forward movement,
from the day of surgery until endpoint: 14 days (2W: acute)
or 70 days (10W: chronic) following SCI. During the 2 weeks
of continuous combinatorial administration of ion channel
inhibitors, treated animals (of Cohort 1 and 2) demonstrated
significant improvement in locomotor function compared to
control as early as 1 day and sustained until up to 14 days
post-SCI (p ≤ 0.05). No significant differences in locomotor
movements were observed between control and treated groups
from 21 days to 70 days post-SCI (Cohort 2; p ≤ 0.05; Figure 3;
Cohort 2 data shown).
Ion Channel Inhibitor Treatment Reduced
Cyst Size and Acute Reactive Gliosis
Following SCI
Cyst formation was calculated as a percentage of the damaged
area relative to spared tissue, within each spinal cord segment,
2- and 10-weeks following SCI. Treatment with ion channel
inhibitors significantly reduced the cyst area, compared to the
relative control groups at 2W (F(1,22) = 3.126, p = 0.0303).
However, there was no significant reduction in cyst size following
treatment at 10W (F(1,22) = 1.73, p = 0.462). Similarly, cyst size
did not change across time for either control (F(1,22) = 0.153,
p = 0.460) or treated animals (p = 0.725; Figures 4A,B). To
determine whether the combination of ion channel inhibitors
modified the inhibitory environment surrounding the injury
site, the effects of ion channel inhibitors on reactive astrogliosis
were assessed. Semi-quantification of GFAP immunoreactivity
demonstrated that treated animals at 2 weeks post-SCI had
significantly reduced intensity above threshold compared to
2-week controls (F(1,22) = 3.677, p = 0.009). However, no effects
of treatment were observed between treated and control animals
at 10 weeks post-SCI (F(1,22) = 0.028, p = 0.734). Although a
significant difference was observed between 2W control and
10W control animals (F(1,22) = 4.629, p = 0.001), there was
no significant difference between 2W treated and 10W treated
animals (F(1,22) = 1.330, p = 0.7347; Figures 4C,D).
Ion Channel Inhibitor Treatment Promoted
Changes in βIII-Tubulin Immunoreactivity,
but Not Regenerative Capacity, Within
Spared Axons During Acute SCI
To determine whether the combinatorial ion channel inhibitor
therapy preserved axonal integrity and/or promoted axonal
sprouting/regeneration following SCI, βIII-tubulin (Roskams
et al., 1998) SMI32 (Carriedo et al., 1996), and GAP43 (Aigner
et al., 1995) immunoreactivity were semi-quantified. Following
SCI, 2W treated animals had a significant increase in βIII-
tubulin intensity above threshold compared to 2W controls
(F(1,22) = 4.279, p = 0.002). This effect was not observed in
10W treated animals (F(1,22) = 0.292, p > 0.999). Again, there
was a significant difference between 2W control and 10W
control animals (F(1,22) = 6.277, p < 0.001), however the same
difference was not observed between 2W treated and 10W
treated animals (F(1,22) = 2.022, p = 0.290; Figures 5A,B).
To further determine whether this significant effect was due
to sparing of βIII-tubulin positive axons, the area above
threshold, indicative of the number of axons within an
area (each ROI), was also analyzed. However, no significant
changes were observed between treated or control animals
(data not shown). Therefore, it is unlikely that the inhibitors
spared axons, but instead there were significant increases
in tubulin immunoreactivity within spared axons, perhaps
due to conformational alterations. There were no significant
differences observed between groups in intensity or area above
threshold of SMI32 immunoreactivity at 2W, or 10W following
SCI (F(1,22) = 0.685, p = 0.0.990; Figures 5C,D). Similarly,
there were no significant effects of treatment (F(1,22) = 0.300,
p = 0.589) or time (F(1,22) = 2.596, p = 0.121) between
animals in GAP43 immunointensity, 2W or 10W following
SCI, suggesting no effect of injury or treatment on axonal
regeneration (Figures 5E,F).
Preservation of MBP Associated With
Density Changes in CC1+ve/NG−ve and
NG2+ve/PDGFα+ve Oligodendroglia During
Acute SCI
To determine the effects of combinatorial ion channel inhibitor
therapy on myelin, oligodendrocytes and their progenitors
following SCI, MBP immunoreactivity was assessed, and the
densities of CC1+ve/NG2−ve mature oligodendrocytes and
NG2+ve/PDGFα+ve OPCs were quantified. Following treatment,
2W animals had no significant changes inMBP immunointensity
(F(1,22) = 0.66, p = 0.987; Figure 6A), but instead were observed
to have a significant increase in MBP immunopositive area
above the threshold, when compared to 2W control animals
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FIGURE 3 | Mean ± SEM locomotor function assessment (BBB) scores in the open field recovery assessment of hindlimb motor function, up to 10 weeks
post-SCI. Animals treated with Lom, oxATP, and YM872 (dashed black line) compared to vehicle-treated control animals (solid black line; *p ≤ 0.05). Red dashed line
represents a typical score of completely uninjured, normal animals (BBB = 21) and the green dashed line represents weight supporting BBB score (BBB = 9). No
significant differences were observed between 2W and 10W cohorts (data not shown), therefore only 10W cohort shown (n = 6–7; n = animal numbers).
FIGURE 4 | Effects of Lom, oxATP, and YM872 on cyst formation and reactive gliosis of GFAP+ve astrocytes, at 2W and 10W post-SCI. (A) Mean ± SEM of cyst
area in toluidine blue-stained spinal cord sections (n = 6–7; *p ≤ 0.05). (B) Representative images of rostral (R) and caudal (C) regions of a single spinal cord section
(scale bar = 5 mm). (C) Mean ± SEM intensity above the threshold of GFAP immunoreactivity (n = 6–7; *p ≤ 0.05). (D) Representative images of areas GFAP+ve
(magenta) immunoreactivity surrounding the injury site (scale bar = 500 µm; n = animal numbers).
(F(1,22) = 3.057, p = 0.0036; Figure 6B). There was an effect of
time, with a significant difference observed between the MBP
immunointensity observed in 2W control and 10W treated
animals (F(1,22) = 4.101, p = 0.003). However, no significant
differences in MBP intensity or area above the threshold
were observed between 10W treated and control animals
(F(1,22) = 0.013, p < 0.999; Figures 6A–C). Quantification
of CC1+ve/NG2−ve cells indicated a significant increase in
mature oligodendrocyte numbers in treated animals compared
to 2W controls (F(1,22) = 4.879, p < 0.001). However, there
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FIGURE 5 | Effects of Lom, oxATP, and YM872 on βIII-tubulin, SMI32, and GAP43, at 2W and 10W post-SCI. (A–F) Mean ± SEM of βIII-tubulin (A), SMI32 (C), and
GAP43 (E), immunointensity above threshold (n = 6–7; *p ≤ 0.05). Representative images show areas of βIII-tubulin+ve (green; B), SMI32+ve (magenta; D) and
GAP43+ve (red; F) immunoreactivity surrounding the injury site (scale bars = 50 µm; n = animal numbers).
were no significant differences between 2W and 10W control
(F(1,22) = 2.102, p = 0.250) or 2W and 10W treated animals
(F(1,22) = 1.72, p = 0.462), and there were no significant
differences in the density of mature oligodendrocytes at 10W
when comparing treated animals and controls (F(1,22) = 0.930,
p = 0. 9327; Figures 6D,E). Quantification of NG2+ve/PDGFα+ve
cells indicated the density of OPCs was significantly increased
at 2W, following treatment with ion channel inhibitors
(F(1,22) = 5.407, p < 0.001). But, at 10W following SCI,
the significant effect of treatment was no longer present
(F(1,22) = 2.67, p = 0.085). Also, there was a significant
reduction in OPCs when comparing 10W treated to 2W
treated animals (F(1,22) = 6.610m p < 0.001), but no difference
between 2W and 10W controls (F(1,22) = 1.891, p = 0.366;
Figures 6F,G).
Ion Channel Inhibitor Treatment Limited
Lipid Peroxidation During Early SCI
The effects of combinatorial ion channel inhibitor therapy on
oxidative by-products caused by lipid peroxidation were also
assessed. Immunohistochemical analysis of lipid peroxidation
by-products revealed 2W treated animals had significant
reductions in both HNE (F(1,22) = 4.090, p = 0.0034) and
Acrolein (F(1,22) = 3.677, p = 0.008) immunoreactivity compared
to 2W control animals. Although there was a significant
reduction in HNE immunoreactivity with time when comparing
2W and 10W control animals (F(1,22) = 6.134, p < 0.001),
there were no significant effects of treatment on HNE
(F(1,22) < 0.001, p> 0.999) or Acrolein (F(1,22) = 0.003, p> 0.999)
immunoreactivity at 10W following SCI (Figures 7A–D).
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FIGURE 6 | Effects of Lom, oxATP, and YM872 on myelin basic protein (MBP) and oligodendroglia sub-populations, at 2W and 10W post-SCI. (A) Mean ± SEM
intensity above the threshold, and (B) mean ± SEM area above the threshold of MBP (n = 6–7; ∗p ≤ 0.05). (C) Representative images show areas of MBP+ve
(magenta) immunoreactivity surrounding the injury site. White arrows demonstrate large area regions where MBP was not detected (scale = 50 µm). (D) Mean ± SEM
mature oligodendrocytes cells per mm 2 (n = 6–7; *p ≤ 0.05). (E) Representative images show the density of CC1+ve NG2−ve mature oligodendrocytes (green;
indicated by white arrows) surrounding the injury site (scale = 25 µm). (F) Mean ± SEM OPCs per mm2 (n = 6–7; *p ≤ 0.05). (G) Representative images show the
density of NG2+ve/PDGFα+ve OPCs (green/red; indicated by white arrows) surrounding the injury site (scale = 25 µm; n = animal numbers).
DISCUSSION
The current study was designed to assess the efficacy of
a combination of ion channel inhibitors; Lom, oxATP,
and YM872, in a clinically relevant rodent model of the
contusion-injured spinal cord. This combination of inhibitors
has been previously assessed in well established, high throughput
in vitro and in vivo models of acute and chronic CNS injury,
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FIGURE 7 | Effects of Lom, oxATP, and YM872 on lipid peroxidation by-products, 4-hydroxynonenal (HNE), and acrolein, at 2W and 10W post-SCI. (A–D)
Mean ± SEM intensity above the threshold of lipid peroxidation by-products 4-hydroxynonenal (HNE) (A) and acrolein (C; n = 6–7; *p ≤ 0.05). Representative images
show areas of HNE+ve (blue; B) and acrolein+ve (cyan; D) immunoreactivity surrounding the injury site (scale bars = 500 µm; n = animal numbers).
consistently demonstrating significant beneficial effects on Ca2+
influx, cell death, oxidative stress, myelin and node of Ranvier
changes, as well as visual function (Savigni et al., 2013; O’Hare
Doig et al., 2014). This study aimed to assess the effects
of the ion channel inhibitor combination on key events of
CNS injury, during the acute (2 weeks) and chronic time
phases (10 weeks) following SCI. Following treatment with ion
channel inhibitors, there was a significant increase in acute
functional hindlimb recovery and reduced formation of cystic
structures and reactive gliosis surrounding the injury site. These
changes were associated with acute increases in βIII-tubulin
and myelin protein immunoreactivity, as well as significant
effects on oligodendrocytes and their progenitors, and significant
reductions in lipid peroxidation products, acrolein, and HNE.
However, all observed effects of treatment (observed acutely)
were not seen in chronic SCI animals, once delivery of oxATP
and YM872 was removed.
In this study, treatment with Lom, YM872, and oxATP
together caused a significant increase in the intensity of βIII-
tubulin+ve profiles surrounding the injury site, in the thoracic
spinal cord. This was associated with reduced formation of cystic
structures, as well as improved functional recovery. However,
following 10-week treatment, despite an acute reduction of
cyst size (increased tissue-sparing), the immunointensity of
β-III tubulin staining, and animal locomotor recovery were
no longer significantly different from vehicle control. This
suggests the treatment effect is only in the first 2 weeks
following SCI when all inhibitors are present. β-III tubulin is
a protein associated with dynamic microtubule extension in
neurons (Lee et al., 1990) and although not neuronal-specific,
is a useful indicator of re-growing axons (Avwenagha et al.,
2003). However, there was no significant increase in GAP43,
a marker expressed in elevated levels during development
and regeneration, and shown to be up-regulated in growing
axons following compressive SCI (Curtis et al., 1993). Thus,
it is unlikely that the combination of ion channel inhibitors
promoted the regeneration of axons, or altered the endogenous
regenerative capacity of these neurons. Instead, the treatment
resulted in acute changes in βIII-tubulin profiles within spared
axons, independent of GAP43 upregulation. This may be due
to increased (at least temporally) microtubule stabilization,
known to reduce scarring and promote axon regeneration after
SCI (Hellal et al., 2011). This is plausible, given the increase
in βIII-tubulin profiles and a decrease in cyst area seen in
untreated SCI animals, temporally (2W control vs. 10W control
animals). Interestingly, no significant effects of treatment were
observed in SMI32+ve profiles (large, mature motor neurons).
This may further highlight a selective vulnerability to damage
and/or stress of different sub populations of neurons, as shown
previously (Morrison et al., 1996; Saroff et al., 2000; Greene
et al., 2005; Ren et al., 2005; Wang and Michaelis, 2010).
Compared to bipedal primates, quadrupedal mammals typically
have a much greater reliance on sensory input from limbs
to drive load-bearing spinal locomotor movements. Therefore,
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rodents typically are much more capable of supported hindlimb
stepping in the absence of supraspinal input (Côté et al.,
2017). Given the final BBB scores of the current study are
in the range of 12–14 (chronic animals), we speculate that
there is likely little preservation of supraspinal control driving
hindlimb functional recovery. As such, final BBB scores are
not entirely reflective of the persistent reduction in cyst size
(tissue preservation) that was achieved with combinatorial
treatment at 2- and 10-weeks post-injury. Inclusion of other
functional tests such as the Louisville Swim Scale (Smith
et al., 2006) where tactile inputs from fore- and hindlimb are
diminished could confirm the extent of supraspinal damage. In
conjunction, future studies could combine dye tracing antero-
and retrograde dye tracing techniques with an assessment of
the density of subpopulations of neurons and their axonal
projections, utilizing additional neuronal markers including, but
not limited to: calcitonin gene-related peptide to assess sensory
neurons (Wiesenfeld-Hallin et al., 1984) and tryptophan, and
tyrosine hydroxylase to assess dopaminergic and serotonergic
neurons, respectively. Changes in the population of individual
subpopulations of cells may reflect specific effects of ion
channel inhibitors on particular neuronal subtypes (Van Den
Bosch et al., 2000), and may provide greater insight and
additional utility for the treatment of SCI. While the effects
of the inhibitor combination on axons are not yet fully
elucidated, there is a clear association observed between
myelin, oligodendrocyte populations, and lipid peroxidation
surrounding the injury site.
We have previously demonstrated a host of
pathophysiological events that occur during secondary
degeneration, including the formation of free radicals, associated
with lipid peroxidation (O’Hare Doig et al., 2014). HNE has
been shown to rapidly accumulate and consequently inhibit
glutamate uptake, following SCI, causing neuronal dysfunction
and apoptosis (Springer et al., 1997). Similarly, protein-bound
acrolein has also been observed to accumulate, up to 7 days
following compressive SCI (Luo et al., 2005). In a recent acute
study of partial optic nerve injury, we showed that treatment
with Lom, oxATP, and YM872 in combination, reduced various
elements of oxidative stress, including lipid peroxidation
(O’Hare Doig et al., 2017) associated with preservation of OPCs.
In the current study, the acute effects of these inhibitors on
by-products of lipid peroxidation were associated with acute
changes to MBP immunoreactivity in the injured spinal cord,
at 2 weeks, but not 10 weeks following SCI. Similarly, the
temporal reduction of HNE was associated with an increase
in myelin profiles seen in non-treated control animals (2W
vs. 10W). Oligodendrocytes are known to be vulnerable to
oxidative damage following neurotrauma, particularly during
proliferative phases and the genesis of myelin sheaths (Juurlink
et al., 1998; Roth and Nunez, 2016; Giacci et al., 2018b). ROS,
hypochlorous acid, and hydrogen peroxide, along with reactive
nitrogen species, hydroxyl radicals and peroxynitrite are likely
contributors to the destruction of oligodendroglia following
CNS injury (O’Hare Doig et al., 2014). The current study
demonstrated a significant increase in the density of OPCs and
mature oligodendrocytes following a 2-week treatment with
inhibitors, associated with reduced lipid oxidation. Interestingly,
however, at 10 weeks, there was no significant reduction in
the number of OPCs observed in treated animals, compared
to 10-week control animals, associated with a lack of change in
HNE and Acrolein. It has been established previously that the
differentiation of OPCs into mature oligodendrocytes occurs
in response to demyelination (Fancy et al., 2004). Therefore,
the increased density of OPCs observed in 2 weeks treated
animals may be a response to changes in myelin proteins
(e.g., MBP), indicated by changes in MBP immunopositive
areas. The increased number of CC1+ve acutely may reflect the
early survival of OPCs, which then differentiate into mature
oligodendrocytes. Previous studies have demonstrated changes
in proliferation and migration of the oligodendrocyte and
OPC populations in response to demyelination following SCI
(Keirstead et al., 1998; Totoiu and Keirstead, 2005). However,
it is as yet unclear whether the observed changes in mature
oligodendrocytes are the cause of MBP changes in the present
study, in turn driving the accumulation and then differentiation
of OPCs (Sim et al., 2002) Alternatively, an acute selective
vulnerability of oligodendroglia to oxidative damage may be
the underlying cause of myelin changes, and observed density
changes of oligodendrocytes, and their progenitors, following
SCI treatment (Back et al., 1998, 2001; Giacci et al., 2018b).
Specifically, delayed oxidative damage in the sub-population of
oligodendroglia may account for the decrease in numbers of
OPCs observed in treated animals at 10 weeks following SCI,
compared to 2 weeks. However, this interpretation remains a
matter of speculation. Therefore, future assessment of myelin
status using established electronmicroscopymeasures (i.e., ratio)
are warranted.
This is the first study to assess the effects of combined Lom,
oxATP, and YM872 treatment in a clinically relevant model of
SCI and provides early indications of efficacy of acute treatment.
In this initial study, we have demonstrated efficacy with 2 weeks
of treatment, however, further work will be needed in future
studies to distinguish between the lack of sustained treatment
or lack of efficacy to explain the 10-week outcome. Like many
injury and disease state models, differences in treatment delivery,
anatomy, physiology and relative scale between humans and
other mammals leads to difficulties in interpretation. Rodent
models of SCI provide a plethora of advantages compared to
non-human primate models, with several reproducible methods
well described, including established behavioral assessments
(for an extensive review see Hodgetts et al., 2009). Several
studies have shown the successful treatment of CNS injury using
osmotic mini-pumps in rodents. However, many of these studies
do not demonstrate efficacy following chronic implantation
in the spinal cord, either due to experimental design (only
measuring acute time points), complications exacerbated by
the implantation of the pump, such as tissue ablation, catheter
failure, dislodgment or obstruction, and inconsistent/adverse
drug delivery (de Yebenes et al., 1987; Bear et al., 1990; Lu
and Hagg, 1997; Angel et al., 1998; Hodgetts et al., 2013).
These limitations demonstrate the difficulty of microinfusing
blood-brain-barrier impermeable agents which must be given
directly to the spinal cord and/or injury site. Despite such
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difficulties, we have demonstrated that the combined delivery
of Lom, oxATP, and YM872 is associated with acute beneficial
effects following SCI. However, chronic administration of oxATP
and/or YM872 is likely needed to further improve the changes,
such as functional improvements, seen at 2 weeks. Due to
experimental design, we do not know if surgical procedures
involving the removal of osmotic mini-pumps administrating
these reagents, exacerbated further secondary events following
SCI that were not measured in the current study, potentially
hindering further functional improvements that may have
resulted from the acute treatment. A literature review indicates
that the longer-term effects of surgically removing osmotic
mini-pumps have not been examined in depth (Jones and
Tuszynski, 2001) and need to be explored further. Similarly,
future studies should incorporate plasma/serum sampling to
ensure the longitudinal functionality of the osmotic mini-pumps
and inhibitor stability. Similarly, for clinical use, it will be
necessary for future studies to determine how long after injury
the combined treatment can be delayed, and efficacy maintained.
In our optic nerve transection model, delayed combinatorial
treatment by 6 h resulted in improvements in visual function,
and the associated reduction in oxidative stress indicators (Yates
et al., 2017). This suggests, time-delayed treatment (clinically
relevant to acute SCI) of ion channel inhibitors remains a
therapeutically viable option. In contrast, it might be that the
ion channel inhibitors slow the rate of tissue loss, but ultimately
not the final amount which may be due to impaired blood flow.
This could be exploited as a way of buying time at the scene
of emergency whilst patients are transported for more definitive
treatments (e.g., decompressive surgery), and could be assessed
in the acute phase (≤72 h) in pre-clinical studies.
Regardless, the current study was designed to assess the
particular combination of inhibitors shown to be efficacious
following partial optic nerve transection, in a clinically relevant
model of SCI. However, to overcome the difficulties of
microinfusion, blood-brain-barrier permeable drug alternatives
are worth pursuing. Peng et al. (2009) found that an analog
FD&C blue dye, No. 1, Brilliant Blue G (BBG), can be used
to selectively antagonize P2X7 receptors in vivo, due to its low
toxicity (Remy et al., 2008), high selectivity (Jiang et al., 2000)
and ability to cross the Bbb (Peng et al., 2009). Administration
of BBG reduced cord damage and improved motor recovery,
associated with reduced inflammatory and glial activation, and
infiltration (Peng et al., 2009). The combination of systemically
administered Lom, YM872, and BBG have shown good effects
in a rodent model of repeated mild traumatic brain injury and
comparable to local delivery at improving outcomes following
partial optic nerve transection (Mao et al., 2018; Toomey et al.,
2019). Therefore, future studies should assess the effects of
systemic delivery of blood-brain-barrier permeable Lom and
YM872 (Nishiyama et al., 1999) with BBG, following SCI.
CONCLUSION
This study provides empirical evidence for the utility of
combinatorial ion channel inhibitor treatment regimens to
facilitate acute improvements in hindlimb functional recovery,
following contusive SCI. We have provided evidence that
significant positive changes in early functional recovery and
pathophysiology can be achieved acutely with a combinatorial
treatment employing Lom, oxATP and YM872 ion channel
inhibitors following SCI, including reduced cyst formation
and glial reactivity, increased tubulin, reduced demyelination
and lipid peroxidation by-products, and changes in mature
oligodendrocytes and their progenitors. Very few studies
show similar marked improvements in locomotor function at
such early time points. Oxidative stress modulation may be
beneficial for other acute injury regimes that have shown or
show promise, utilizing a combinatorial approach. However,
the observed beneficial effects appear to be governed by
the method and/or length of delivery of the treatment,
highlighting the importance of both an acute therapeutic
window and a longitudinal treatment regime. Therefore,
future studies should further assess the efficacy of ion channel
inhibitor combinations in chronic models of SCI, incorporating
therapeutic timing and clinical validity, improved drug delivery
mechanisms, bio-activity/availability, and/or blood-brain-
barrier permeability properties.
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